Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

43
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
43
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

64
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
64
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

58
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
58
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

31
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
31
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

123
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
123
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

58
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
58

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robotic Magnetic Navigation Versus Manual Catheter Ablation for Premature Ventricular Contractions: A Single-center Retrospective Cohort Study.

The Journal of innovations in cardiac rhythm management·2026
Same author

REPLY: The Angiographic Veto: Putting the Operator Back in DAPT De-Escalation.

JACC. Cardiovascular interventions·2026
Same author

Percutaneous micro-axial flow pump use during non- emergent high-risk PCI: The authors reply.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Long-Term Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement Among Patients With Prior Mediastinal Radiation.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Contemporary Trends, Characteristics, and Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Stent Thrombosis.

JACC. Cardiovascular interventions·2026
Same author

Contemporary Operator Procedural Volumes and Outcomes for TAVR and MTEER in the US.

JAMA cardiology·2026

Related Experiment Video

Updated: Oct 15, 2025

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

10.1K

Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis.

Ravi A Thakker1, Marissa A Lee1, Aiham Albaeni2

  • 1Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.

Cardiology Research
|October 25, 2021
PubMed
Summary

Immune checkpoint inhibitor (ICI) therapy can cause myocarditis, a serious heart condition. This review of 71 cases found it affects older men, often with hypertension, and has a high mortality rate, necessitating vigilant surveillance.

Keywords:
Cardio-oncologyHeart failureImmune checkpoint inhibitorMyocarditis

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K

Related Experiment Videos

Last Updated: Oct 15, 2025

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

10.1K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K

Area of Science:

  • Cardio-oncology
  • Immunotherapy
  • Oncology

Background:

  • Immune checkpoint inhibitor (ICI) therapy is a vital cancer treatment.
  • ICI therapy is associated with various adverse events, including cardiac complications.
  • Myocarditis is a significant concern in patients receiving ICI therapy.

Purpose of the Study:

  • To analyze individual clinical characteristics and outcomes of patients who developed ICI-related myocarditis.
  • To review existing literature on myocarditis secondary to ICI therapy.

Main Methods:

  • A comprehensive PubMed database review was conducted.
  • Inclusion criteria focused on case reports and case series of patients with ICI-related myocarditis.
  • Studies with individual patient-level data were prioritized, excluding observational studies, trials, systematic reviews, and meta-analyses.

Main Results:

  • 71 cases of ICI-related myocarditis were reviewed.
  • The average patient age was 68 years, with a higher incidence in men.
  • Hypertension was a common pre-treatment cardiac history; melanoma was the most prevalent cancer, and nivolumab the most used ICI.
  • Heart failure was the most frequent co-occurring adverse event.
  • Corticosteroids were the primary treatment, and nearly half of the patients experienced mortality.

Conclusions:

  • ICI-related myocarditis presents with specific patient characteristics and carries a high mortality risk.
  • Cardio-oncologists and internists should implement periodic surveillance for ICI-related myocarditis.
  • Understanding the impact of ICI therapy on myocarditis is crucial given its expanding use in cancer treatment.